EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs

Research output: Contribution to journalReview article

Standard

EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. / Bertsias, GK; Ioannidis, JPA; Aringer, M; Bollen, E; Bombardieri, S; Bruce, IN; Cervera, R; Dalakas, M; Doria, A; Hanly, JG; Huizinga, TWJ; Isenberg, D; Kallenberg, C; Piette, JC; Schneider, M; Scolding, N; Smolen, J; Stara, A; Tassiulas, I; Tektonidou, M; Tincani, A; van Buchem, MA; van Vollenhoven, R; Ward, M; Gordon, Caroline; Boumpas, DT.

In: Annals of the Rheumatic Diseases, Vol. 69, No. 12, 01.12.2010, p. 2074-2082.

Research output: Contribution to journalReview article

Harvard

Bertsias, GK, Ioannidis, JPA, Aringer, M, Bollen, E, Bombardieri, S, Bruce, IN, Cervera, R, Dalakas, M, Doria, A, Hanly, JG, Huizinga, TWJ, Isenberg, D, Kallenberg, C, Piette, JC, Schneider, M, Scolding, N, Smolen, J, Stara, A, Tassiulas, I, Tektonidou, M, Tincani, A, van Buchem, MA, van Vollenhoven, R, Ward, M, Gordon, C & Boumpas, DT 2010, 'EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs', Annals of the Rheumatic Diseases, vol. 69, no. 12, pp. 2074-2082. https://doi.org/10.1136/ard.2010.130476

APA

Bertsias, GK., Ioannidis, JPA., Aringer, M., Bollen, E., Bombardieri, S., Bruce, IN., Cervera, R., Dalakas, M., Doria, A., Hanly, JG., Huizinga, TWJ., Isenberg, D., Kallenberg, C., Piette, JC., Schneider, M., Scolding, N., Smolen, J., Stara, A., Tassiulas, I., ... Boumpas, DT. (2010). EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Annals of the Rheumatic Diseases, 69(12), 2074-2082. https://doi.org/10.1136/ard.2010.130476

Vancouver

Author

Bertsias, GK ; Ioannidis, JPA ; Aringer, M ; Bollen, E ; Bombardieri, S ; Bruce, IN ; Cervera, R ; Dalakas, M ; Doria, A ; Hanly, JG ; Huizinga, TWJ ; Isenberg, D ; Kallenberg, C ; Piette, JC ; Schneider, M ; Scolding, N ; Smolen, J ; Stara, A ; Tassiulas, I ; Tektonidou, M ; Tincani, A ; van Buchem, MA ; van Vollenhoven, R ; Ward, M ; Gordon, Caroline ; Boumpas, DT. / EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. In: Annals of the Rheumatic Diseases. 2010 ; Vol. 69, No. 12. pp. 2074-2082.

Bibtex

@article{57ed31619dd4410f8e44228549ab2bff,
title = "EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs",
abstract = "Objectives To develop recommendations for the diagnosis, prevention and treatment of neuropsychiatric systemic lupus erythematosus (NPSLE) manifestations. Methods The authors compiled questions on prevalence and risk factors, diagnosis and monitoring, therapy and prognosis of NPSLE. A systematic literature search was performed and evidence was categorised based on sample size and study design. Results Systemic lupus erythematosus (SLE) patients are at increased risk of several neuropsychiatric manifestations. Common (cumulative incidence >5%) manifestations include cerebrovascular disease (CVD) and seizures; relatively uncommon (1-5%) are severe cognitive dysfunction, major depression, acute confusional state (ACS), peripheral nervous disorders psychosis. Strong risk factors (at least fivefold increased risk) are previous or concurrent severe NPSLE (for cognitive dysfunction, seizures) and antiphospholipid antibodies (for CVD, seizures, chorea). The diagnostic work-up of suspected NPSLE is comparable to that in patients without SLE who present with the same manifestations, and aims to exclude causes unrelated to SLE. Investigations include cerebrospinal fluid analysis (to exclude central nervous system infection), EEG (to diagnose seizure disorder), neuropsychological tests (to assess cognitive dysfunction), nerve conduction studies (for peripheral neuropathy) and MRI (T1/T2, fluid-attenuating inversion recovery, diffusion-weighted imaging, enhanced T1 sequence). Glucocorticoids and immunosuppressive therapy are indicated when NPSLE is thought to reflect an inflammatory process (optic neuritis, transverse myelitis, peripheral neuropathy, refractory seizures, psychosis, ACS) and in the presence of generalised lupus activity. Antiplatelet/anticoagulation therapy is indicated when manifestations are related to antiphospholipid antibodies, particularly thrombotic CVD. Conclusions Neuropsychiatric manifestations in SLE patients should be first evaluated and treated as in patients without SLE, and secondarily attributed to SLE and treated accordingly.",
author = "GK Bertsias and JPA Ioannidis and M Aringer and E Bollen and S Bombardieri and IN Bruce and R Cervera and M Dalakas and A Doria and JG Hanly and TWJ Huizinga and D Isenberg and C Kallenberg and JC Piette and M Schneider and N Scolding and J Smolen and A Stara and I Tassiulas and M Tektonidou and A Tincani and {van Buchem}, MA and {van Vollenhoven}, R and M Ward and Caroline Gordon and DT Boumpas",
year = "2010",
month = dec
day = "1",
doi = "10.1136/ard.2010.130476",
language = "English",
volume = "69",
pages = "2074--2082",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "12",

}

RIS

TY - JOUR

T1 - EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs

AU - Bertsias, GK

AU - Ioannidis, JPA

AU - Aringer, M

AU - Bollen, E

AU - Bombardieri, S

AU - Bruce, IN

AU - Cervera, R

AU - Dalakas, M

AU - Doria, A

AU - Hanly, JG

AU - Huizinga, TWJ

AU - Isenberg, D

AU - Kallenberg, C

AU - Piette, JC

AU - Schneider, M

AU - Scolding, N

AU - Smolen, J

AU - Stara, A

AU - Tassiulas, I

AU - Tektonidou, M

AU - Tincani, A

AU - van Buchem, MA

AU - van Vollenhoven, R

AU - Ward, M

AU - Gordon, Caroline

AU - Boumpas, DT

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Objectives To develop recommendations for the diagnosis, prevention and treatment of neuropsychiatric systemic lupus erythematosus (NPSLE) manifestations. Methods The authors compiled questions on prevalence and risk factors, diagnosis and monitoring, therapy and prognosis of NPSLE. A systematic literature search was performed and evidence was categorised based on sample size and study design. Results Systemic lupus erythematosus (SLE) patients are at increased risk of several neuropsychiatric manifestations. Common (cumulative incidence >5%) manifestations include cerebrovascular disease (CVD) and seizures; relatively uncommon (1-5%) are severe cognitive dysfunction, major depression, acute confusional state (ACS), peripheral nervous disorders psychosis. Strong risk factors (at least fivefold increased risk) are previous or concurrent severe NPSLE (for cognitive dysfunction, seizures) and antiphospholipid antibodies (for CVD, seizures, chorea). The diagnostic work-up of suspected NPSLE is comparable to that in patients without SLE who present with the same manifestations, and aims to exclude causes unrelated to SLE. Investigations include cerebrospinal fluid analysis (to exclude central nervous system infection), EEG (to diagnose seizure disorder), neuropsychological tests (to assess cognitive dysfunction), nerve conduction studies (for peripheral neuropathy) and MRI (T1/T2, fluid-attenuating inversion recovery, diffusion-weighted imaging, enhanced T1 sequence). Glucocorticoids and immunosuppressive therapy are indicated when NPSLE is thought to reflect an inflammatory process (optic neuritis, transverse myelitis, peripheral neuropathy, refractory seizures, psychosis, ACS) and in the presence of generalised lupus activity. Antiplatelet/anticoagulation therapy is indicated when manifestations are related to antiphospholipid antibodies, particularly thrombotic CVD. Conclusions Neuropsychiatric manifestations in SLE patients should be first evaluated and treated as in patients without SLE, and secondarily attributed to SLE and treated accordingly.

AB - Objectives To develop recommendations for the diagnosis, prevention and treatment of neuropsychiatric systemic lupus erythematosus (NPSLE) manifestations. Methods The authors compiled questions on prevalence and risk factors, diagnosis and monitoring, therapy and prognosis of NPSLE. A systematic literature search was performed and evidence was categorised based on sample size and study design. Results Systemic lupus erythematosus (SLE) patients are at increased risk of several neuropsychiatric manifestations. Common (cumulative incidence >5%) manifestations include cerebrovascular disease (CVD) and seizures; relatively uncommon (1-5%) are severe cognitive dysfunction, major depression, acute confusional state (ACS), peripheral nervous disorders psychosis. Strong risk factors (at least fivefold increased risk) are previous or concurrent severe NPSLE (for cognitive dysfunction, seizures) and antiphospholipid antibodies (for CVD, seizures, chorea). The diagnostic work-up of suspected NPSLE is comparable to that in patients without SLE who present with the same manifestations, and aims to exclude causes unrelated to SLE. Investigations include cerebrospinal fluid analysis (to exclude central nervous system infection), EEG (to diagnose seizure disorder), neuropsychological tests (to assess cognitive dysfunction), nerve conduction studies (for peripheral neuropathy) and MRI (T1/T2, fluid-attenuating inversion recovery, diffusion-weighted imaging, enhanced T1 sequence). Glucocorticoids and immunosuppressive therapy are indicated when NPSLE is thought to reflect an inflammatory process (optic neuritis, transverse myelitis, peripheral neuropathy, refractory seizures, psychosis, ACS) and in the presence of generalised lupus activity. Antiplatelet/anticoagulation therapy is indicated when manifestations are related to antiphospholipid antibodies, particularly thrombotic CVD. Conclusions Neuropsychiatric manifestations in SLE patients should be first evaluated and treated as in patients without SLE, and secondarily attributed to SLE and treated accordingly.

U2 - 10.1136/ard.2010.130476

DO - 10.1136/ard.2010.130476

M3 - Review article

C2 - 20724309

VL - 69

SP - 2074

EP - 2082

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 12

ER -